Life Sciences Research for Lifelong Health

Type

News

Babraham and the Alzheimer's Agenda

Babraham Group Leader, Michael Coleman took part in a panel discussion on Alzheimer’s Disease (AD).  The event, organised by Oxbridge Biotech Roundtable, was aimed at bringing leading industry, academic, and policy stakeholders together to share their opinion regarding all aspects of the current AD pandemic.  

The panel covered means of diagnosis and treatment and how to manage and effectively treat Alzheimer’s disease in the near future.  Points of discussion also involved the coordination of governmental efforts to build research resources, the reengineering of current drug development and evaluation systems, and the identification of innovative technologies and financing models. Cambridge offers an ideal, highly interdisciplinary environment uniquely positioned for holding a wider discussion on Alzheimer’s disease.

Many research laboratories, like Prof Coleman's team at Babraham, are based in this area, and Cambridge is home to Alzheimer’s Research UK (ARUK), the nation's leading dementia research charity, and to the newly opened Cambridge-Elan Centre for Research Innovation and Drug Discovery, which focuses precisely on delivering world-leading translational research focused on innovative therapies for Alzheimer’s. 


ARUK-funded work in Prof Coleman's group at Babraham focusses on how Alzheimer's disease disrupts nerve cells and their synapses. The group is also funded by the Biotechnology and Biological Sciences Research Council (BBSRC) to study related processes during normal ageing. Coleman said: "Since ageing is the biggest risk factor for Alzheimer's disease, these complementary goals are vital for understanding how these processes influence one another".

Posted

28 January, 2014